Audited Financial Results for the quarter and year ended March 31, 2025
Awaiting price reaction for this filing.
Gland Pharma's Board approved audited standalone and consolidated financial results for Q4 and FY25, with statutory auditor Deloitte Haskins & Sells issuing an unmodified (clean) opinion. The Board recommended a final dividend of Rs. 18 per share (1800% on face value of Rs. 1) for FY25, subject to shareholder approval at the 47th AGM on August 28, 2025, with record date set as August 14, 2025. The Board also appointed M/s. RVR & Associates as Secretarial Auditors for a five-year term starting April 1, 2025. Several internal policies related to subsidiaries, related party transactions, insider trading, and whistleblower protection were updated to align with recent SEBI amendments.
Clean audit opinion and a robust dividend payout signal financial health and shareholder-friendly capital allocation. The dividend record date of August 14, 2025 is the key actionable date for investors seeking to qualify for the final dividend.